Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"ImmuPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immupharma\u2019s Efforts in the Fight Against Covid-19 with Lupuzor\u2122 and Ureka","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"ImmuPharma","sponsor":"Avion Pharmaceuticals","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"ImmuPharma provides an update on the Avion Agreement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III"},{"orgOrder":0,"company":"ImmuPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA confirms December 4 2020 for Type \u2018A\u2019 Meeting to Discuss Guidance on ImmuPharma's Forthcoming International Phase 3 Trial of Lupuzor\u2122","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III"},{"orgOrder":0,"company":"ImmuPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 2\/3 Adaptive Clinical Trial of P140 (Lupuzor) in Lupus to Commence Following FDA Meeting","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals by ImmuPharma

    Menu

    ImmuPharma

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              ImmuPharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Phase 2/3 Adaptive Clinical Trial of P140 (Lupuzor) in Lupus to Commence Following FDA Meeting

              Details:

              Lupuzor (Forigerimod) have unique mechanism of action involves modulating the activation of auto-reactive T-cells, which is investigated for treatment of systemic lupus erythematosus.

              Lead Product(s): Forigerimod

              Therapeutic Area: Immunology Product Name: Lupuzor

              Highest Development Status: Phase III Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 19, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ImmuPharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              FDA confirms December 4 2020 for Type ‘A’ Meeting to Discuss Guidance on ImmuPharma's Forthcoming International Phase 3 Trial of Lupuzor™

              Details:

              As part of the Type ‘A’ Meeting, Avion has asked the FDA for guidance on the Key aspects of the study design, clinical end points and approval process for Lupuzor™; and Consideration by the FDA for a conditional approval of Lupuzor™, whilst the Phase 3 trial is underway.

              Lead Product(s): IPP-201101

              Therapeutic Area: Immunology Product Name: Lupuzor

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 20, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ImmuPharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Immupharma’s Efforts in the Fight Against Covid-19 with Lupuzor™ and Ureka

              Details:

              Investigation of the application of the Ureka peptide technologies within the Antivirals program suggests the potential to create effective anti-fusion peptides with the goal to prevent virus entry into the host cells, which may lead to novel peptide based antiviral therapies.

              Lead Product(s): IPP-201101

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 14, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ImmuPharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ImmuPharma provides an update on the Avion Agreement

              Details:

              Avion and ImmuPharma to meet with the FDA in Q1 2020 to discuss guidance on a new optimised international Phase III trial protocol.

              Lead Product(s): Rigerimod

              Therapeutic Area: Immunology Product Name: Undisclosed

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Avion Pharmaceuticals

              Deal Size: $100.0 million Upfront Cash: Undisclosed

              Deal Type: Agreement February 06, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY